Suppr超能文献

抗体在开发靶向G蛋白偶联受体二聚体的药物中的作用。

Role of antibodies in developing drugs that target G-protein-coupled receptor dimers.

作者信息

Hipser Chris, Bushlin Ittai, Gupta Achla, Gomes Ivone, Devi Lakshmi A

机构信息

Department of Pharmacology and Systems Therapeutics, Mount Sinai School of Medicine, New York, NY, USA.

出版信息

Mt Sinai J Med. 2010 Jul-Aug;77(4):374-80. doi: 10.1002/msj.20199.

Abstract

G-protein-coupled receptors are important molecular targets in drug discovery. These receptors play a pivotal role in physiological signaling pathways and are targeted by nearly 50% of currently available drugs. Mounting evidence suggests that G-protein-coupled receptors form dimers, and various studies have shown that dimerization is necessary for receptor maturation, signaling, and trafficking. However, the physiological implications of dimerization in vivo have not been well explored because detection of GPCR dimers in endogenous systems has been a challenging task. One exciting new approach to this challenge is the generation of antibodies against specific G-protein-coupled receptor dimers. Such antibodies could be used as tools for characterization of heteromer-specific function; as reagents for their purification, tissue localization, and regulation in vivo; and as probes for mapping their functional domains. In addition, such antibodies could serve as alternative ligands for G-protein-coupled receptor heteromers. Thus, heteromer-specific antibodies represent novel tools for the exploration and manipulation of G-protein-coupled receptor-dimer pharmacology.

摘要

G蛋白偶联受体是药物研发中的重要分子靶点。这些受体在生理信号通路中起关键作用,目前近50%的可用药物都以它们为靶点。越来越多的证据表明,G蛋白偶联受体可形成二聚体,各种研究表明,二聚化对于受体成熟、信号传导和运输是必要的。然而,由于在内源系统中检测GPCR二聚体一直是一项具有挑战性的任务,二聚化在体内的生理意义尚未得到充分探索。应对这一挑战的一种令人兴奋的新方法是生成针对特定G蛋白偶联受体二聚体的抗体。此类抗体可用作表征异源二聚体特异性功能的工具;用作其纯化、组织定位和体内调节的试剂;以及用作绘制其功能域的探针。此外,此类抗体可作为G蛋白偶联受体异源二聚体的替代配体。因此,异源二聚体特异性抗体代表了探索和操纵G蛋白偶联受体二聚体药理学的新型工具。

相似文献

1
Role of antibodies in developing drugs that target G-protein-coupled receptor dimers.
Mt Sinai J Med. 2010 Jul-Aug;77(4):374-80. doi: 10.1002/msj.20199.
2
GPCR heteromers: An overview of their classification, function and physiological relevance.
Front Endocrinol (Lausanne). 2022 Aug 30;13:931573. doi: 10.3389/fendo.2022.931573. eCollection 2022.
3
Physiological relevance of GPCR oligomerization and its impact on drug discovery.
Drug Discov Today. 2008 Dec;13(23-24):1059-66. doi: 10.1016/j.drudis.2008.09.002. Epub 2008 Oct 14.
4
GPCR homomers and heteromers: a better choice as targets for drug development than GPCR monomers?
Pharmacol Ther. 2009 Nov;124(2):248-57. doi: 10.1016/j.pharmthera.2009.07.005. Epub 2009 Aug 5.
5
Contribution of heteromerization to G protein-coupled receptor function.
Curr Opin Pharmacol. 2017 Feb;32:23-31. doi: 10.1016/j.coph.2016.10.006. Epub 2016 Nov 9.
6
Antibodies to probe endogenous G protein-coupled receptor heteromer expression, regulation, and function.
Front Pharmacol. 2014 Dec 3;5:268. doi: 10.3389/fphar.2014.00268. eCollection 2014.
7
G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives.
Pharmacol Rev. 2014 Feb 10;66(2):413-34. doi: 10.1124/pr.113.008052. Print 2014.
8
Bivalent ligands as specific pharmacological tools for G protein-coupled receptor dimers.
Curr Drug Discov Technol. 2008 Dec;5(4):312-8. doi: 10.2174/157016308786733591.
9
Identification of a μ-δ opioid receptor heteromer-biased agonist with antinociceptive activity.
Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):12072-7. doi: 10.1073/pnas.1222044110. Epub 2013 Jul 1.
10
G Protein-Coupled Receptor Heteromers in Brain: Functional and Therapeutic Importance in Neuropsychiatric Disorders.
Annu Rev Pharmacol Toxicol. 2025 Jan;65(1):215-236. doi: 10.1146/annurev-pharmtox-061724-080727.

引用本文的文献

1
Contributions of the International Narcotics Research Conference to Opioid Research Over the Past 50 years.
Adv Drug Alcohol Res. 2022 Feb 18;2:10115. doi: 10.3389/adar.2022.10115. eCollection 2022.
2
Membrane-Mediated Oligomerization of G Protein Coupled Receptors and Its Implications for GPCR Function.
Front Physiol. 2016 Oct 25;7:494. doi: 10.3389/fphys.2016.00494. eCollection 2016.
3
Current approaches for the discovery of drugs that deter substance and drug abuse.
Expert Opin Drug Discov. 2014 Nov;9(11):1319-31. doi: 10.1517/17460441.2014.956721. Epub 2014 Sep 24.
4
Unidirectional cross-activation of GRPR by MOR1D uncouples itch and analgesia induced by opioids.
Cell. 2011 Oct 14;147(2):447-58. doi: 10.1016/j.cell.2011.08.043.
5
Therapeutic antibodies directed at G protein-coupled receptors.
MAbs. 2010 Nov-Dec;2(6):594-606. doi: 10.4161/mabs.2.6.13420. Epub 2010 Nov 1.

本文引用的文献

1
Allosteric modulators of g protein-coupled receptors: future therapeutics for complex physiological disorders.
J Pharmacol Exp Ther. 2009 Nov;331(2):340-8. doi: 10.1124/jpet.109.156380. Epub 2009 Aug 10.
3
Bivalent ligands as specific pharmacological tools for G protein-coupled receptor dimers.
Curr Drug Discov Technol. 2008 Dec;5(4):312-8. doi: 10.2174/157016308786733591.
4
Multiple ligands in opioid research.
Protein Pept Lett. 2008;15(7):668-82. doi: 10.2174/092986608785133672.
6
Antibodies against G-protein coupled receptors: novel uses in screening and drug development.
Comb Chem High Throughput Screen. 2008 Jul;11(6):463-7. doi: 10.2174/138620708784911465.
7
Identification of a serotonin/glutamate receptor complex implicated in psychosis.
Nature. 2008 Mar 6;452(7183):93-7. doi: 10.1038/nature06612. Epub 2008 Feb 24.
8
Post-activation-mediated changes in opioid receptors detected by N-terminal antibodies.
J Biol Chem. 2008 Apr 18;283(16):10735-44. doi: 10.1074/jbc.M709454200. Epub 2008 Feb 6.
9
Hemopressin is an inverse agonist of CB1 cannabinoid receptors.
Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20588-93. doi: 10.1073/pnas.0706980105. Epub 2007 Dec 12.
10
Humanization of antibodies.
Front Biosci. 2008 Jan 1;13:1619-33. doi: 10.2741/2786.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验